Kevin Mayo, Ph.D., E.JD

Kevin Mayo, Ph.D., E.JD has extensive experience in the field of market access, health economics, and value strategy in the biotechnology and pharmaceutical industries. Kevin currently serves as the Senior Vice President of Market Access and Health Economics at Rapid Commercialization Partners, where they advise emerging biotechnology companies on market access and health economic strategies.

Prior to their current role, Mayo held various senior positions at Jazz Pharmaceuticals, AstraZeneca, and Agilis Biotherapeutics Inc. At Jazz Pharmaceuticals, they served as the Senior Director of Oncology Global Value Lead, where they played a key role in optimizing clinical trial designs and evidence generation for payers and stakeholders worldwide.

Before joining Jazz Pharmaceuticals, Mayo was the Director of Value Strategy and Evidence at AstraZeneca, where they contributed to the strategic planning and evidence generation for the US market access contracting.

Mayo also founded and served as the Managing Partner of Value Genome LLC, a consulting firm specializing in market access, health economics, outcomes research, and medical affairs for late-stage clinical development companies in oncology, gene therapy, and rare diseases.

Furthermore, Mayo has held positions at Massachusetts Institute of Technology, Baxalta (acquired by Shire), Research Partnership, Endo Pharmaceuticals, and Bridgehead International. These roles involved responsibilities such as managing global market access functions, negotiating pricing and reimbursement with government and commercial payers, and conducting market research on payer and pricing strategies.

Overall, Kevin Mayo's work experience demonstrates their expertise in market access and health economics, specifically in the biotechnology and pharmaceutical sectors.

Kevin Mayo, Ph.D., E.JD has an extensive education history in various fields. Kevin obtained their Bachelor's degree in Pharmaceutical Marketing and Administration from the University of Louisiana at Monroe in 1996. Following that, Dr. Mayo pursued a Master of Science (M.S.) degree in Neuropsychology from The University of Memphis, specializing in Patient Reported Outcomes and Outcomes Research between 1991 and 1993.

Dr. Mayo then furthered their education by completing a Post Doctoral program in Health Economics and Outcomes Research at the State University of New York College of Medicine in 1997. In 2010, they pursued a Juris Doctor degree in Health Law and Health Policy at Concord Law School, earning an E.JD.

In addition to their formal education, Dr. Mayo has also acquired various certifications. These certifications include "J.T. O'Donnell on Making Recruiters Come to You" and "Value-Based Pricing" from LinkedIn in 2016, "Healthcare Compliance" from Seton Hall Law School in 2013, and "Certified Pricing Professional" from the Professional Pricing Society in 2009. Furthermore, Dr. Mayo obtained a Moral Recognition Therapy Certification in 1990.

Dr. Kevin Mayo has continued to expand their knowledge and expertise through participation in courses and programs. Kevin became a TAG Member for Gene Therapies and Durable Oncology Agents at the Massachusetts Institute of Technology (MIT) from 2016 to 2020 and also became a Therapeutic Advisor specializing in Financing and Reimbursement of Cures in the USA, with a focus on Gene Therapies and Durable Oncology Agents (CAR-Ts) from 1996 to 2018, both at MIT.

Overall, Dr. Kevin Mayo's education history demonstrates a strong foundation in pharmaceutical marketing and administration, neuropsychology, health law, health policy, and gene therapies.